SEARCH

SEARCH BY CITATION

References

  • 1
    Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 218592.
  • 2
    Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha- granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694702.
  • 3
    Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 2005; 25: 8616.
  • 4
    Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
  • 5
    Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 88390.
  • 6
    Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 11389.
  • 7
    Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in ‘‘acquired’’ hemophilia. Arterioscler Thromb Vasc Biol 2003; 23: 1239.
  • 8
    Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17: S15.
  • 9
    He S, Blomback M, Ekman GJ, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 12159.
  • 10
    Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JCM, Nieuwenhuis HK, De Groot PG. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 1759.
  • 11
    Persson E, Olsen OH, Ostergaard A, Nielsen LS. Ca2+ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity. J Biol Chem 1997; 272: 1991924.
  • 12
    Sorensen BB, Persson E, Freskgard PO, Kjalke M, Ezban M, Williams T, Rao LVM. Incorporation of an active-site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 118638.
  • 13
    Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 11420
  • 14
    Ezban M, Chapman B, Petersen J, Hansen K, Rasmussen PB, Thomsen J, Kjalke M, Kongerslev L. Characterization of recombinant human two chain factor VIII. Thromb Haemost 1993; 69 (Suppl. 1): 1088 Abstract 1946.
  • 15
    Freskgard PO, Olsen OH, Persson E. Structural-changes in factor VIIa induced by Ca2+ and tissue factor studied using circular-dichroism spectroscopy. Protein Sci 1996; 5: 153140.
  • 16
    Jandrot-Perrus M, Lagrue AH, Okuma M, Bon C. Adhesion and activation of human platelets induced by convulxin involve glycoprotein-VI and integrin α2β1. J Biol Chem 1997; 272: 2703541.
  • 17
    Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin α2β1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for α2β1-independent platelet reactivity. Biochem J 1995; 306: 33744.
  • 18
    Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 40213.
  • 19
    Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 5427.
  • 20
    Dale GL, Friese P. Bax activators potentiate coated-platelet formation. J Thromb Haemost 2006; 4: 26649
  • 21
    Bevers EM, Janssen MP, Comfurius P, Balasubramanian K, Schroit AJ, Zwaal RFA, Willems GM. Quantitative determination of the binding of β2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets. Biochem J 2005; 386: 2719
  • 22
    Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Bairdcox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharm Therapeutics 1994; 55: 63848.
  • 23
    Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Comm 2001; 281: 3069.
  • 24
    Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 45661.
  • 25
    Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of hemophilia. Br J Haematol 2006; 134: 31419.
  • 26
    Batar P, Dale GL. Simultaneous engagement of thrombin and Fc gamma RIIA receptors results in platelets expressing high levels of procoagulant proteins. J Lab Clin Med 2001; 138: 393402.
  • 27
    Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 92330.
  • 28
    Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 2003; 1: 4505.
  • 29
    Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 1006.
  • 30
    Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899909.